Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata by Matthew G Hawkins et al.
Hawkins et al. Virology Journal 2013, 10:137
http://www.virologyj.com/content/10/1/137RESEARCH Open AccessDetection of specific HPV subtypes responsible
for the pathogenesis of condylomata acuminata
Matthew G Hawkins1†, David M Winder1†, Siolian L R Ball1, Katie Vaughan1, Christopher Sonnex2,
Margaret A Stanley1, Jane C Sterling1,3 and Peter K C Goon1,2*Abstract
Background: The low-risk human papillomavirus types 6 and 11 are responsible for approximately 90% of
anogenital wart cases, with approximately 190,000 new and recurrent cases reported in the UK in 2010. The UK has
recently selected the quadrivalent HPV vaccine, which conveys protection against both HPV6 and HPV 11, as part of
its immunisation programme for 2012 and it is expected that this will reduce disease burden in the UK. The aims of
the study were to evaluate current strategies used for the monitoring of HPV infection in genital warts and to
assess the suitability of laser-capture microdissection (LCM) as a technique to improve the understanding of the
natural history of HPV types associated with genital wart lesions.
Methods: DNA and RNA were extracted from whole wart, surface swabs and LCM sections from 23 patients. HPV
types present were determined using the Linear Array HPV Genotyping Test (Roche), with HPV DNA viral load and
mRNA expression investigated using qPCR and qRT-PCR, respectively.
Results: Results indicated that swabbing the surface of warts does not accurately reflect potential causative HPV
types present within a wart lesion, multiple HPV types being present on the surface of the wart that are absent in
the lower layers of tissue isolated by LCM. Although it was shown that HPV DNA viral load does not directly
correlate with HPV mRNA load, the presence of both DNA and mRNA from a single HPV type suggested a causative
role in lesion development in 8/12 (66.6%) of patients analysed, with dual infections seen in 4/12 (33.3%) cases. HPV
6 and HPV 11 were present in more than 90% of the lesions examined.
Conclusions: Surface swabbing of warts does not necessarily reflect the causative HPV types. HPV type specific
DNA and mRNA loads do not correlate. HPV 6 and 11 were likely to be causally involved in over 90% of the lesions.
Dual infections were also found, and further studies are required to determine the biological and clinical nature of
dual/multiple infections and to establish the relationship of multiple HPV types within a single lesion.
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Human papillomavirus (HPV) is the aetiological cause of
anogenital warts. Anogenital wart disease is the most com-
mon sexually transmitted disease, affecting millions world-
wide every year. In 2010, approximately 190,000 new and
recurrent cases were reported through GU clinics in the
UK [1], with the low-risk HPV types (LR-HPV) 6 and 11* Correspondence: pg336@cam.ac.uk
†Equal contributors
1Department of Pathology, University of Cambridge, Tennis Court Road,
Cambridge, CB2 1QP, UK
2Department of Genito-Urinary Medicine, Box 38, Addenbrooke’s Hospital,
Hills Road, Cambridge, CB2 0QQ, UK
Full list of author information is available at the end of the article
© 2013 Hawkins et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpredominating in the pathogenesis of the common ano-
genital wart, or condyloma acuminatum [2]. The licensing
of the prophylactic quadrivalent vaccine Gardasil (Merck)
in 2007, which conveys protection against HPV types 6
and 11 in addition to the high-risk types HPV 16 and 18,
has now raised the real prospect of reducing the disease
burden of anogenital warts in society. It has already been
shown that a high coverage of eligible females (approxi-
mately 80%) has resulted in a 73% fall in incident genital
warts in Australian women since 2007 [3]. These observa-
tions indicate a potentially large impact on disease burden
elsewhere. The UK has recently selected the quadrivalent
HPV vaccine as part of its immunisation programme forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments to the NHS in the UK is thought to be as high as
£52.4 million [1].
Most epidemiological studies on wart disease have in-
volved swabbing of the surface of lesions with subse-
quent HPV typing being undertaken on the extracted
DNA [4-7]. Interestingly, studies have also documented
that multiple infections with several different HPV sub-
types are common [8-10]. In the cervix it has recently
been shown that a lesion is almost always associated
with a single HPV type, although there can be several le-
sions abutting each other, and thus give the impression
of a single lesion [11]. Wart lesions may also reflect such
a pattern, but a thorough analysis in a similar manner
has not been previously reported. The question therefore
remains, whether the multiplicity of HPV types reported
from genital wart swabs is genuinely reflective of the
types causally associated with the lesion.
The aim of this study was to determine whether surface
swabbing of warts accurately reflects the HPV type or
types causing the epidermal proliferation. Surface con-
tamination with other HPV types was determined by
comparing the HPV types found in swab samples to
those present in whole wart tissue, using the Linear
Array HPV genotyping test (Roche). Laser-capture mi-
crodissection (LCM) was then used to isolate the surface
and the basal areas for further analyses, permitting the
identification of potential candidate HPV types respon-
sible for the wart lesion. Furthermore, HPV DNA and
mRNA, thought to be the “gold-standard” by which HPV
type is linked with cervical lesion progression [12-14],
were quantified and compared with the Linear Array
data. RNA analysis was used as the final arbiter of HPV
activity within the wart, based on the hypothesis that a
transcriptionally active HPV type is associated with ac-
tual lesion causation. Messenger RNA analysis for HPV
transcriptional activity also eliminates the problem of
surface contamination with “bystander” virus, as HPV
gene transcription is fully dependent on cellular replica-
tion machinery [15]. The suitability of surface swabbing
as a method for the detection of HPV types present in
anogenital warts is discussed.
Results
HPV typing was performed by utilising DNA extracted
from swabs and whole wart tissue in 23 samples, and
the upper and lower layers of wart tissue dissected out
using laser-capture microdissection (LCM) in 16 out of
23 patients. Figure 1 shows typical examples of the use of
laser-capture microdissection (LCM) for obtaining tissue
specific to the areas intended for analysis. LCM was used
to determine the likelihood of surface contamination by
dissecting out the upper and lower layers of wart tissue.
These layers acted as comparative controls for surfacecontamination, both positive and negative, respectively –
as the upper layer includes the potentially contaminated
external wart surface (including stratum corneum and
stratum granulosum) and the lower layer includes the
uncontaminated stratum spinosum and stratum basale.
The prevalence of HPV types present in the whole wart,
swabs, and the upper and lower microdissected layers, clas-
sified into either low-risk or high-risk (Table 1). The five
most common HPV types detected via the Linear array
method in wart tissue were HPV 6 (82.6% of all samples),
HPV 16 (43.5%), HPV 45 (34.8%), HPV 11 (17.4%) and
HPV 42 (13.0%). In swabs, the five most common types of
HPV present were HPV 6 (78.2%), HPV 16 (47.8%), HPV
45 (26.1%), HPV 51 (21.7%) and HPV 84 (17.4%). In the
lower layers of warts, HPV 6 was by far the dominant type
and was found in 75.0% of samples analysed. HPV 45 was
next most common (31.3%) and HPV 52 was third (18.8%).
In the upper layers of tissue, HPV 6 was again dominant
(75.0%), followed by HPV 16 (37.5%), and third was HPV
81 (31.3%).
There was very good concordance between HPV types
detected between swabs and whole tissue, particularly
for HPV 6, HPV 11 and HPV 31 (κ = 0.862, 0.832 and
1.000, respectively). Furthermore, substantial agreement
(0.80 ≥ κ > 0.60) (κ = 0.646) occurred for both HPV
types 59 and 81. No concordance was observed (κ ≤ 0) for
HPV 16, HPV 52, HPV 53 or HPV 54. Remaining HPV
types exhibited at least fair agreement (κ > 0.20). Overall
concordance for all types found between whole wart tissue
and swabs was κ = 0.574 (moderate agreement).
The overall concordance for all HPV types detected
between upper and lower layers of wart tissue was κ =
0.632 (substantial agreement). However, when compared
with whole wart tissue, both upper and lower layers only
exhibited moderate agreement (κ = 0.490 and 0.538,
respectively). Furthermore, concordance estimates for
HPV 6 was reduced from κ = 1.000 (perfect agreement
in upper vs lower analyses) to substantial (κ = 0.600 for
both wart vs upper and wart vs lower). HPV 11 was also
reduced from κ = 1.000 to moderate (κ = 0.429 for
both). This suggests that the LCM tissue is not represen-
tative of its corresponding whole wart tissue in terms of
HPV types detected.
HPV types were subsequently classified as surface
contamination, undetermined or infection candidates,
dependent on the presence or absence of HPV in the tissue
samples analysed (Table 2). These categories were derived
from the assumption that HPV types found in the interior
or basal areas of warts are likely to be involved in the
pathogenesis of the wart lesion. Hence, infection candi-
dates are those subtypes identified from [lower layers +
(whole wart – upper layers)]. Likely surface contaminants
are [(upper layers – lower layers) + (swab + whole wart –
lower layers) + (swab – whole wart)].
Figure 1 Capture of wart tissue using Laser-Capture Microdissection. The series of photographs identifies the sequential extraction of lower
and upper layers within wart tissue. Tissues a – f are histological specimens of wart tissue stained with either H&E (left-most column) or cresyl
violet (other columns). Scale bar for image = 300 um, except tissue e = 250 um.
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were performed for HPV 6, HPV 11, HPV 16, HPV 45
and 52 (Table 3). These HPV types were the most preva-
lent types in the list of infection candidates, with the ex-
ception of HPV 11. HPV 11 was chosen because it is
known to be a common type associated with warts. HPV
6 and HPV 11 were seen to be the dominant types, in
terms of both DNA viral loads and mRNA expression.
Four lesions exhibited mixed RNA expression, implying
multiple actively replicating HPV types in the lesion:
sample 4 (HPVs 6 and 11), sample 9 (HPVs 6 and 11),
sample 11 (HPVs 6 and 11) and sample 12 (HPVs 11and 16). No correlation between DNA viral load and
mRNA expression was seen in wart tissue for HPV 6,
which was the predominant type found in this cohort
(p = 0.3034, Spearman’s Rank Correlation Coefficient,
2 tailed test).
Potential infection candidates, identified by subtracting
probable and confirmed contaminant types, were then
compared to the HPV types with confirmed expression
from the mRNA analysis (Table 4). Poor correlation
was found between potential infection candidates and
HPV types with mRNA expression. Only 10/17 (58.8%)
candidates from the RNA positive list were found to be
Table 1 HPV type identification in whole wart tissue, swabs, lower and upper layers of wart tissue
Sample # Whole wart tissue Swab Lower layer Upper layer
Low risk High risk Low risk High risk Low risk High risk Low risk High risk
1 6, 42 59 6, 42, 84, CP* 58, 59 11 - 11, 81 16, 45
2 6 16 6, 55 16 6 45, 52 6 -
3 6 16 6 16 6 18, 45, 52 6 16, 52
4 6 - 6, 84 53, 59 6, 81 45 6, 81 16
5 6 16, 45, 53 6 16, 45, 52, 53, 66 6 53 6 53
6 6 - 6 73 6 - 6 -
7 6, 11, 81 - 6 16, 18 6 - 6 -
8 6 33, 52 6 16 6 - 6, 81 -
9 6 16 6 16 6 - 6 -
10 6 - 6 45, 52 6 - 6 16, 18, 31, 52
11 6, 55 16, 45 55 51 55 - 55 53
12 11, 81 16 11, 81 16 11, 81 16 11, 81 16
13 6 16 6 16 6 16, 45 6 -
14 6 45 6 45, 51 6 45, 52 6 -
15 6, 55 16, 45, 52 6 - 6 - 6 16
16 55 16, 31, 45 CP* 16, 18, 31, 45, 51, 66 54 31 54, 81 31
17 11 - 11 - ** **
18 6 18, 33, 45, 52 6 16 ** **
19 6 45 6, 84 45 ** **
20 6, 42 - 6 18 ** **
21 6, 42 45, 51 6, 42 45, 51, 67, 82 ** **
22 11 16 11, 84 - ** **
23 6 51 6, 62 16, 51 ** **
Roche linear array genotyping was performed on 23 individual patients using 50 ng DNA, and the HPV types identified. CP* abbreviated for CP6108 and is now
known as HPV 89. **Insufficient DNA.
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HPV 6 was found in the undetermined category. In four
cases (samples 3, 4, 9 and 11), HPV 11 was not found
by the Linear Array system. These cases illustrate the
fact that use of mRNA expression (as opposed to pure
DNA analyses alone) will aid final conclusions. Finally,
only 76.5% of candidates identified by elevated mRNA
levels were included in the list of potential or undeter-
mined infection candidates.
Discussion
Anogenital warts is the most common sexually transmit-
ted disease in the world, and is also a marker of trans-
mission of high-risk HPV types, such as HPV 16 and
HPV 18, due to similar infection routes. Diagnosis with
genital warts is associated with a long-term increased
risk of anogenital and head and neck cancers [16]. The
monitoring of clinically obvious disease, such as ano-
genital warts, therefore has an important bearing upon
overall HPV disease in the community at large. It is ac-
cepted that HPV 6 and HPV 11 are the dominant typesin the pathogenesis of anogenital warts and in the upper
respiratory tract equivalent, respiratory papillomatosis
[17]. However, it is also known that other benign or low-
risk types have been implicated in the causation of ano-
genital warts [5,10,18-20]. One potential confounding
factor in these studies is that surface swabbing of lesions
for HPV DNA, a commonly used method to define the
HPV types involved, is susceptible to contamination with
unrelated HPV types.
In this study, laser-capture microdissection was used
to facilitate the delineation of HPV types likely to be sur-
face contaminants from those likely to be involved in
the aetiology of the wart lesion. Subsequent real-time
PCR analyses for both E6 DNA and E6 mRNA allowed
their suitability for monitoring purposes to be deter-
mined. The use of simple equations, based on the prem-
ise that HPV types identified from within the deeper
epithelium of the wart are more likely to be causal,
allowed “infection candidates” to be identified. Messen-
ger RNA detection for five common HPV types found in
this cohort was then used to identify the most likely
Table 2 Identification of potential surface contaminants
and infection candidates






1 16, 45, 58, 81, 84, CP$ 6, 42, 59 11, 81
2 55 16 6, 45, 52
3 16 - 6, 18, 45, 52
4 16, 53, 59, 84 - 6, 45, 81
5 52, 66 16, 45 6, 53
6 73 - 6
7 16, 18, 81 11 6, 42, 59
8 16, 81 33, 52 6
9 - 16 6
10 16, 18, 31, 45, 52 - 6
11 51, 53 6, 16, 45 55
12 - - 11, 16, 81
13 - - 6, 16, 45
14 51 - 6, 45, 52
15 16 45, 52, 55 6
16 18, 51, 66, 81, CP$ 16, 45, 55 31, 54
17** - 11 -
18** 16 6, 18, 33, 45, 52 -
19** 84 6, 45 -
20** 18 6, 42 -
21** 67, 82 6, 42, 45, 51 -
22** 84 11, 16 -
23** 16, 62 6, 51 -
Data from each sampling technique was compared, and likely contaminants
were identified and potential infection candidates were determined: - infection
candidates are those subtypes identified from [lower layers + (whole wart –
upper layers)]. Likely surface contaminants are [(upper layers – lower layers) +
(swab + whole wart – lower layers) + (swab – whole wart)]. *Absence of HPV type
in swab, lower and upper layers cannot rule out possibility of contamination (since
wart tissue contains both contaminants and non-contaminants). ** Absence of
LCM cannot confirm any HPV type as truly non-contaminant. CP$ abbreviated for
CP6108 and is now known as HPV 89.
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HPV 6 was a more frequent cause of lesions than HPV
11. Interestingly, the majority of HPV types identified as
surface contaminants were high-risk types (75%), with
the remainder being identified as low-risk types (25%).
The majority of contaminant HPV types featured only
once or twice in the samples (incidence <8%). HPV 16
was the most common surface contaminant (25% of
wart lesions). Interestingly, many of the surface contami-
nants detected via the LCM and typing analyses were
high-risk types and we speculate that perhaps high-risk
types have an innate survival advantage over many low-
risk types (with the exception of HPV 6 and 11, whichare very successful wart developers) and this aids their
transmission rates.
The incidence of multiple infections detected in wart
studies ranges from 33.8% to 40.1% when using only
swabbing techniques [10,21], as well as 21.7% when
using fresh wart tissue specimens [22]. These infections
were a mixture of high-risk and low-risk types (range:
2–5 types) but usually contained HPV 6 or 11, or both.
In our cohort, 28.6% anogenital warts were co-infected
with active (E6 mRNA+) HPV types, similar to the
published estimates discussed above. However, it is
important to note that this statistic is two-fold less
than the co-infection levels observed for the DNA
detection methods and without exclusion of surface
contamination. Therefore existing data concerning
multiple infections may be an overestimate. On the
other hand, it is possible that the suspected multiple
infections are in fact two different lesions growing
together and appearing as a single lesion, as has been
shown for the cervix [11]. Quint et al. demonstrated
that for the cervix, a single lesion is most often asso-
ciated with a single HPV type. Where multiple types
were found, careful laser-capture microdissection of
histopathological sections found that different types
were associated with several abutting lesions, but
with the over-riding conclusion that each type caused
a single lesion. There are no data to suggest that two
or more types of HPV can infect a single cell and
this study does not address that question.
Moderate concordance exists between whole wart tis-
sue and corresponding swabs in terms of HPV detection
(κ = 0.574), with high concordance levels for HPV types
6, 11, 31, 59 and 81. This illustrates that anogenital
swabs can be used with reasonable reliability to deter-
mine HPV types detected in whole wart tissue. However,
this study has also shown that HPV DNA viral load esti-
mates from swab samples do not reflect that which is
observed in paired wart tissue. Furthermore, the elucida-
tion of surface contamination highlights potential limita-
tions with non-adjusted HPV prevalence data obtained
from swab samples [5,10,18,23] and also disagrees with
the claim that HPV identification in swabs can be used
for analysing clinical changes in a specific lesion. It
would thus seem apparent that careful consideration
may be needed concerning the existing literature on
HPV prevalence in anogenital warts. However, the use of
swabs for monitoring the effects of vaccination and
treatment [20] is likely to remain valid.
Interestingly, the lack of correlation between DNA
viral loads and mRNA expression suggests that measur-
ing viral DNA levels is not representative of viral activ-
ity within the wart. It is possible that the efficiency of
the viral transcription machinery differs between indi-
vidual viruses. Alternatively, it is possible that either the
Table 3 Comparing HPV DNA viral loads and RNA levels in whole wart tissue
Sample HPV DNA viral load (copies/cell) HPV RNA level (copies/μg RNA
HPV6 HPV11 HPV16 HPV45 HPV52 HPV6 HPV11 HPV16 HPV45 HPV52
1 45.71 0 0* 0* 0 191.25 0 0* 0* 0
2 213.05 0.01 0.04 0 0 370 0 0 0 0
3 101.47 0 0* 0 0 0 0.34 0* 0 0
4 333.88 0 0* 0.03 0.05 186.77 26.88 0* 0 0
5 10974.83 0 115.18 0.35 0* 45.53 0 0 0 0.04*
6 13303.58 0 0.05 0 0 2047.98 0 0 0 0
7 218.29 0 0.03* 0 0 900.90 0 0* 0 0
8 604.56 0.01 0.03* 0 0 1341.49 0 0* 0 0
9 161.60 0 0.03 0 0 70.61 20.81 0 0 0
10 171.66 0 0.01* 0* 0* 5883.86 0 0* 0* 0*
11 279.68 0.01 0.18 0 0.02 856.98 43.52 0 0 0
12 0.01 4.31 172.88 0 0 0 51.15 17.20 0 0
13 571.85 0 0 0 0 - - - - -
14 48.47 0 0 0 0 - - - - -
15 0.22 0 0.41* 0 0 - - - - -
16 0 0 0.10 0 0.01 - - - - -
17 0 3.07 0.02 0 0 0 439.28 0 0 0
18 171.74 0 0.04* 0 0 0 0 0* 0 0
19 422.87 - - - - - - - - -
20 36.35 0.01 0 0 0 - - - - -
21 206.25 0.09 0.04 0 0 - - - - -
23 22.61 0.06 0* 0 0 - - - - -
HPV DNA viral loads (viral copies/cell) and RNA transcript levels (copies/μg RNA) were obtained by qPCR and qRT-PCR, respectively. (−) indicates that there was
insufficient material for analyses. Samples containing HPV types previously determined as a likely contaminant (refer to Table 2) have been highlighted with an
asterisk (*) and excluded from any further analysis.
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nents using the methods employed vary or there is a
differing level of viral E6 gene expression during vari-
ous stages of the virus replication lifecycle.
The importance of HPV 6 and HPV 11 in the patho-
genesis of classic condylomata acuminata has been dem-
onstrated here, and has been deemed to be causal in
over 90% of this small cohort of 23 patients. These data
therefore support published studies in the literature.
There has however, been little RNA work performed in
wart disease which could serve to either support or re-
fute this finding, only previous publications which quote
the 90% level of causation for these two dominant types
[24,25]. It may be that the total amount of clinical wart
disease prevented via the L1 prophylactic vaccine will be
similarly high or even higher. Furthermore, if herd im-
munity of human populations around the world can be
achieved utilising currently available L1 prophylactic
vaccines, rare diseases such as recurrent respiratory
papillomatosis (RRP) will also be reduced but this will
require long-term population surveillance.The detailed and thorough molecular work involved in
this small study has revealed that, although multiple in-
fections are apparently a frequent occurrence when de-
termined by swabbing wart lesions, the actual numbers
of types potentially involved in lesion pathogenesis is
low. This is an important and potentially confounding
factor in all studies that involve only the surface swab-
bing of wart lesions. We also show for the first time
that laser capture microdissection can be utilised suc-
cessfully to assist in objective analyses of the aetiology
of anogenital warts, but there was poor correlation with
detected RNA levels. This technique is expensive and
requires specialised skills and is likely to remain a re-
search tool only.
In this study, samples 4, 9, 11 and 12 demonstrated evi-
dence of dual infection. Interestingly, HPV 16 was shown
be elevated for both DNA and mRNA in sample 12,
which is evidence of active replication in that lesion. In
four cases (samples 3, 4, 9 and 11), HPV 11 was not
found by the Linear Array system. The reason for this is
not known but may be related to sensitivity levels. The
Table 4 Identification of candidate HPV types causing
wart lesion development
Sample # Infection candidates
(refer Table 2)
Potential cause of lesion
(RNA analyses)
1 11, 81 6b
2 6a, 45, 52 6a
3 6, 18, 45, 52 11d
4 6a, 45, 81 6a, 11d
5 6a, 53 6a, 52c
6 6a 6a
7 6a, 42, 59 6a
8 6a 6a
9 6a 6a, 11d
10 6a 6a
11 55 6b, 11d
12 11a, 16a, 81 11a, 16a
17** - 11b
Identification of candidate HPV types causing warts by HPV E6 RNA as arbiter
of type involvement compared to laser capture & microdissection (LCM) with
DNA typing.*Absence of HPV type in swab, lower and upper layers cannot
rule out possibility of contamination (since wart tissue contains both
contaminants and non-contaminants). **Absence of LCM cannot confirm any
HPV type as truly non-contaminant. CP$ abbreviated for CP6108 and is now
known as HPV 89. HPV types correctly identified as infection candidates
are highlighted by superscript (a); HPV types identified as potentially causing
lesion development in the ‘undetermined’ category are highlighted by
superscript (b); HPV types incorrectly identified as surface contaminants
have been highlighted by superscript (c); HPV types potentially causing wart
lesion development but not detected using Linear Array are highlighted by
superscript (d).
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detect HPV 11 plasmids at a level of 900 copies/ml
and it is possible that the virus is present with a DNA
quantity lower than this detection threshold. The data
shows that HPV 6 or HPV 11 appear to be involved
causally in a majority of lesions clinically diagnosed as
typical condylomata acuminata. The data also suggests
a potential role for HPV 16 or other types in isolated
cases of wart disease and this hypothesis needs to be
explored in further studies.
Methods
Study samples
Clinical samples were obtained from patients attend-
ing the Departments of Gynaecological Oncology and
Dermatology, Addenbrooke's Hospital, Cambridge, UK.
Ethical approval was obtained from the local research
ethics committee (Cambridgeshire 3 REC reference no:
07/H0306/127) and all patients gave written informed
consent for the use of these samples for this study.
Anogenital warts were excised as part of treatment
and dissected into five equal segments using sterilised
scalpel blades, following which they were frozen in li-
quid nitrogen until DNA extraction. Prior to excision,a concomitant Dacron swab sampled the anogenital wart
surface. The swab was agitated in PBS and discarded. The
cells obtained from the swab sample were suspended in
PBS and stored at −20°C prior to DNA extraction.
Laser-capture microdissection (LCM)
One segment of sample was removed from liquid nitro-
gen and thawed on ice. Fresh unfixed tissue segments
were embedded in optimal cutting temperature (OCT)
compound. Multiple 7 μm OCT-embedded sections were
sliced and mounted to PEN (polyethylene naphthalate)
membrane coated slides (Leica Microsystems Ltd., UK),
being stored at −70°C prior to LCM. An additional sec-
tion of tissue was sliced onto Biobond-coated Superfrost
slides (VWR International, UK) and stained with haema-
toxylin and eosin (H&E) in order to allow tissue strata to
be identified.
Prior to LCM, slide-bound tissue sections were stained
with cresyl violet. Tissue dehydration was performed
by a series of alcohol baths for 1 minute (70, 95 and
100% ethanol). Lipids were removed from the tissue
by bathing in 1:1 chloroform:ethanol for 3 minutes.
The tissue was then rehydrated (1 minute in 95%
then 70% ethanol and H2O) and stained with 0.4%
cresyl violet solution for 10 seconds and immediately
washed with distilled water to remove any residual
staining medium. Sections were allowed to dry prior
to transportation on ice.
LCM of frozen tissue sections was performed using
Leica LMD7000 Laser Microdissection System (Leica
Microsystems Ltd., UK). The slide was inverted and
fixed under the microscope where a 0.5 μm laser beam
was used to dissect selected areas of tissue. Dissected tis-
sue was allowed to fall into a collecting tube, containing
40 μl PBS, placed underneath the inverted slide as
summarised in video format, http://www.jove.com/index/
Details.stp?ID=309 [26]. The collection tube was stored
on ice until DNA extraction. Dissections were performed
in triplicate.
DNA extraction and HPV typing
Samples of whole wart tissue were inserted into a FastPrep
lysing matrix tube (MP Biomedicals Europe, Illkirch,
France) and disrupted in a Bullet Blender™ (Next Advance
Inc., Averill Park, USA) prior to genomic DNA (gDNA) ex-
traction [27]. gDNA was extracted from PBS containing
debris from swabs using the DNeasy Blood and Tissue Kit
(QIAGEN Ltd., Crawley, UK) according to a modified
protocol [28]. gDNA was purified from LCM samples
using the DNeasy Blood and Tissue Kit (QIAGEN Ltd.,
UK), according to the manufacturer's instructions.
The Roche Linear Array HPV Genotyping Test (LA
HPV GT - Roche Diagnostics Ltd., Burgess Hill, UK),
allowing detection of 37 high- and low-risk HPV types,
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structions [29].
mRNA extraction and cDNA synthesis from whole wart
tissue
RNA was extracted from whole wart tissue, as previously
described [8]. Briefly, tissue was suspended in 200 μl
Trizol™ (Invitrogen, Paisley, UK) in a lysing matrix D tube
(MP Biomedicals, Solon, OH) and pulverized using a
Bulletblender™ machine (Next Advance, Averill Park, NY).
RNA was precipitated with isopropranol and resuspended
in 50 μl H2O. After DNAse I digestion, RNA was recov-
ered by column purification using PureLink™ RNA extrac-
tion kit (Invitrogen) following manufacturer’s instructions
and a maximum of 5 μg reverse transcribed using
Bioscript™ (Bioline, London, UK) after preincubation
with random hexamer primers for 5 min at 65°C. Reactions
were performed as follows: 25°C for 10 min, 42°C for
60 min and 70°C for 15 min. No-RT controls were
performed without the addition of enzyme.
qPCR for HPV E6
The primers and probes targeting the HPV E6 gene for
types 6, 11, 16, 18, 45 and 52, together with human
GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
and β-globin are described elsewhere (20–23). All qPCR
reactions were performed in 20 μl containing 1x PCR
buffer (Qiagen, UK), 4.5 mM MgCl2 (Qiagen, UK), 375
μM dNTPs (Roche, UK), 100 nM primer pairs and probe
(Sigma Genosys, UK), 0.5 units Hotstart Platinum Taq
(Qiagen, UK) and template.
Relative cellular mRNA for HPV E6 was determined
by normalizing HPV values, obtained following qPCR
of wart mRNA, with TBP (TATA-Box binding protein),
YWHAZ (tyrosine 3-mono-oxygenase/tryptophan 5-mono-
oxygenase activation protein, zeta polypeptide) and HMBS
(hydroxymethylbilane synthase) using primers and probes
that have been previously described (24–26).
qPCR amplification was performed using Rotor-Gene
3000 (Corbett Life Sciences). Cycling conditions were as
follows: an initial activation/denaturation step at 95°C
for 15 min, then 40 cycles of 95°C for 15 sec and 60°C
for 60 sec, with acquisition of fluorescent signal at 60 sec.
Data was analysed using the Rotor-Gene analysis software
(version 6.1). The quantification of HPV DNA viral load
and mRNA expression in samples was accomplished
through the use of a standard curve incorporated into each
experiment.
*The choice of E6 DNA and mRNA as a target for our
qPCRs for DNA and RNA viral loads was taken because
E6 and E7 are crucial early proteins active in all alpha-
group papillomavirus replication, DNA synthesis, abort-
ive infections and productive infections but not in latent
infections [30-32].Statistical methods
The concordance and agreement between samples for
each HPV type detected was calculated. Kappa values of
0–0.2 (slight), 0.21-0.4 (fair), 0.41-0.6 (moderate), 0.61-
0.8 (substantial) and 0.81-1.0 (almost perfect) indicated
the level of agreement between the methods used [33].
Statistical analyses were performed with SPSS software.
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